non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant

Drug identity checked against registry records

Also recorded as exemestane; exemestane plus everolimus; fulvestrant

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerNCT05065411VERUPhase 3Terminated2023-10-19Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.